NASDAQ:RLAY Relay Therapeutics Q1 2024 Earnings Report $4.66 +0.11 (+2.42%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$4.70 +0.04 (+0.75%) As of 09/19/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Relay Therapeutics EPS ResultsActual EPS-$0.62Consensus EPS -$0.70Beat/MissBeat by +$0.08One Year Ago EPS-$0.78Relay Therapeutics Revenue ResultsActual Revenue$10.01 millionExpected Revenue$0.12 millionBeat/MissBeat by +$9.89 millionYoY Revenue Growth+4,327.90%Relay Therapeutics Announcement DetailsQuarterQ1 2024Date5/2/2024TimeAfter Market ClosesConference Call DateThursday, May 2, 2024Conference Call Time4:00PM ETUpcoming EarningsRelay Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Relay Therapeutics Earnings HeadlinesRelay Therapeutics, Inc. (RLAY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 10, 2025 | seekingalpha.comRelay Therapeutics (RLAY) Receives a Buy from GuggenheimSeptember 9, 2025 | theglobeandmail.comFed Signals More Rate Cuts—Big Opportunity for Gold?The Fed’s recent rate cut — with more expected before year’s end — has already pushed gold to record highs above $3,700. Each cut makes cash and bonds less appealing, driving investors toward assets like gold. But according to veteran analyst Sean Brodrick, the biggest winners aren’t always gold itself. During past bull runs, select investments tied to gold have soared far higher than the metal. Now, with more rate cuts on the horizon, Sean has identified five opportunities he believes could deliver the strongest gains in this cycle. | Weiss Ratings (Ad)Guggenheim Gives Buy Rating to Relay Therapeutics (RLAY)September 8, 2025 | insidermonkey.comGuggenheim assumes Relay with Buy, names best ideaSeptember 4, 2025 | msn.comRelay Therapeutics assumed with a Buy at GuggenheimSeptember 3, 2025 | msn.comSee More Relay Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Relay Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relay Therapeutics and other key companies, straight to your email. Email Address About Relay TherapeuticsRelay Therapeutics (NASDAQ:RLAY) is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins. The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening. This approach enables Relay to explore conformational changes in proteins that have historically been difficult to target, opening new avenues for therapeutic intervention. Relay’s pipeline comprises multiple preclinical and clinical programs aimed at oncogenic drivers implicated in a range of solid tumors. Relay Therapeutics has progressed a number of assets into human trials, with initial studies evaluating safety, tolerability and preliminary signs of clinical activity. In addition to its internal development programs, the company collaborates with academic institutions and other biopharmaceutical companies to expand the application of its platform across diverse therapeutic areas. Relay’s research efforts are supported by partnerships that bring complementary expertise and resources to accelerate the identification of novel drug candidates. Under the leadership of President and Chief Executive Officer Michael Gilman, Ph.D., Relay Therapeutics continues to advance its vision of precision oncology medicines that address unmet medical needs. The company’s operations are primarily based in the United States, while its clinical trials enroll patients across North America and select international sites. Relay Therapeutics is publicly traded on the Nasdaq under the ticker symbol RLAY.View Relay Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner Upcoming Earnings Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
